Mashup Score: 2
ascopost.comBy The ASCO Post Staff Posted: 2/17/2023 11:13:00 AM Last Updated: 2/17/2023 2:25:11 PM The TALAPRO-2 phase III clinical trial found that combining the poly (ADP-ribose) polymerase (PARP) inhibitor talazoparib with the androgen receptor inhibitor enzalutamide resulted in significantly better progression-free...
TALAPRO-2 – talazoparib + enzalutamide improves progression free survival for men with mCRPC. No data on Overall survival yet. Benefit seen for men with HRD mutations and those without (although greater in those with HRD mutations). Nearly three quarters of men in combination arm had side effects.